NanoViricides
Strengthens
its Board of Directors with Addition of Industry Veteran Brian
Zucker, CPA
SHELTON,
CONNECTICUT -- November 19,
2020 -- InvestorsHub NewsWire -- NanoViricides,
Inc. (NYSE Amer.: NNVC)
(the "Company"), a leader in developing novel nanomedicines to
treat viral diseases, announced today that Mr. Brian Zucker, CPA,
has joined the Company's Board of Directors, effective
November 13,
2020, as an independent director. He was also appointed as a member
of the Board's Audit Committee, Nomination Committee and
Compensation Committee.
Mr.
Zucker is a Partner at CFO Financial Partners, LLC (https://www.cfopartners.com/),
a firm that provides outsourced CFO (Chief Financial Officer),
Controller and Financial Operations services as well as back office
reporting and bookkeeping services for public and private
companies, broker dealers, hedge funds, and family offices and high
net worth individuals, among others. Mr.
Zucker
also
serves as the CFO and Financial Operations Principal for numerous
broker dealers and hedge funds. In addition to and simultaneously
therewith, Mr. Zucker
has
served as a Partner at RRBB Accountants & Advisors, (aka
Rosenberg Rich Baker Berman & Co.), a full-service accounting,
advisory and consulting firm
located in Central New Jersey. He has over thirty
years of experience as a CPA specializing in the securities
industry..
From
1983 through 1986, Mr. Zucker
was a
Senior Consultant at Deloitte Haskins and Sells and at Price
Waterhouse from January 1987 through September 1989. He has
previously served as the President and Chairman of Atlantis
Business Development Corp. (ABDV), CFO of Natcore
Solar
Technology, Inc. (NTCXF) and as a Managing Director of American
Frontier Financial Corp. (EVIS). Since May 2018, he has been
serving as the CFO of EIG Energy Partners Capital Markets,
LLC. Brian holds a CPA in States of New Jersey and New York,
and holds several FINRA licenses. He is on the Board of Directors
of National Investment Banking Association (NIBA).
Mr.
Zucker
obtained a B.S. in
Public Accounting from Pace university.
"
We are pleased to strengthen our Audit Committee and our Board of
Directors with the addition of Mr. Brian Zucker," said Mr. Stan
Glick, CPA, Independent Director and Chair of the Audit Committee,
adding "He brings valuable multi-faceted experience with public
companies, as well as financings and banking institutions to our
Board."
About
NanoViricides
NanoViricides,
Inc. (the "Company")(www.nanoviricides.com)
is a development stage company that is creating special purpose
nanomaterials for antiviral therapy. The Company's novel
nanoviricide®
class of drug candidates are designed to specifically attack
enveloped virus particles and to dismantle them. Our lead drug
candidate is NV-HHV-101 with its first indication as dermal topical
cream for the treatment of shingles rash. In addition, we are
developing a clinical candidate for the treatment of COVID-19
disease caused by SARS-CoV-2 coronavirus. The Company cannot
project an exact date for filing an IND for this drug because of
its dependence on a number of external collaborators and
consultants.
The
Company is now working on performing required safety pharmacology
studies and completing an IND application for its COVID-19 drug
candidate. This drug candidate encapsulates remdesivir
in the
Company's nanoviricide,
which the Company believes could be a potential cure for SARS-CoV-2
infection if it effectively blocks both (a) the intracellular virus
replication (due to remdesivir)
and (b) the extracellular virus particle reinfection (due to the
Company's nanoviricide
component). The
Company believes that since remdesivir
already
is US FDA approved, our drug candidate encapsulating
remdesivir
is
likely to be an approvable drug, depending upon certain human
clinical trials. Remdesivir
is
developed by Gilead. The Company has developed our own drug
candidates independently.
The
Company intends to re-engage into an IND application to the US FDA
for NV-HHV-101 drug candidate for the treatment of shingles once
its COVID-19 project moves into clinical trials, based on resources
availability. The NV-HHV-101 program was slowed down because of the
effects of recent COVID-19 restrictions, and re-prioritization for
COVID-19 drug development work.
The
Company is also developing drugs against a number of viral diseases
including oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu,
seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and
Ebola virus, among others. NanoViricides'
platform technology and programs are based on the
TheraCour®
nanomedicine technology of TheraCour,
which TheraCour
licenses
from AllExcel. NanoViricides
holds a
worldwide exclusive perpetual license to this technology for
several drugs with specific targeting mechanisms in perpetuity for
the treatment of the following human viral diseases: Human
Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV),
Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and
HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu
Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus
and Ebola/Marburg viruses. The Company has executed a Memorandum of
Understanding with TheraCour
that
provides a limited license for research and development for drugs
against human coronaviruses. The Company intends to obtain a full
license and has begun the process for the same. The Company's
technology is based on broad, exclusive, sub-licensable, field
licenses to drugs developed in these areas from TheraCour
Pharma,
Inc. The Company's business model is based on licensing
technology from TheraCour
Pharma
Inc. for specific application verticals of specific viruses, as
established at its foundation in 2005.
This
press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual
events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides,
Inc. are "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. You should not place undue reliance on
forward-looking statements since they involve known and unknown
risks, uncertainties and other factors which are, in some cases,
beyond the Company's control and which could, and likely will,
materially affect actual results, levels of activity, performance
or achievements. The Company assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if
new information becomes available in the future. Important factors
that could cause actual results to differ materially from the
company's expectations include, but are not limited to, those
factors that are disclosed under the heading "Risk Factors" and
elsewhere in documents filed by the company from time to time with
the United States Securities and Exchange Commission and other
regulatory authorities.
Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
preclinical trials that a nanoviricide
is safe
and effective; successful development of our product candidates;
our ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products. FDA refers to US Food and Drug
Administration. IND application refers to "Investigational New
Drug" application. CMC refers to "Chemistry, Manufacture, and
Controls".
Contact:
NanoViricides,
Inc.
info@nanoviricides.com
Public Relations Contact:
MJ
Clyburn
TraDigital
IR
clyburn@tradigitalir.com
Source:
NanoViricides,
Inc.
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2023 to Sep 2024